Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026

REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the U.S. financial markets on Monday, November 9, 2026.

Kamada's management will host an investment community conference call on Monday, November 9, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 13763380. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1779441&tp_key=96a5dea210.